Mantle cell lymphoma: continuously improving the odds!

Bibliography

• Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest oncology group study. Blood 1995;85(4):1075-82
   PubMed Web of Science ®Google Scholar
• Armitage JO. Management of mantle cell lymphoma. Oncology 1998;12(10 Suppl 8):49-55
   PubMedGoogle Scholar
• Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003;97(3):586-91
   PubMed Web of Science ®Google Scholar
• Cheah CY, George A, Gine E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European mantle cell lymphoma network. Ann Oncol 2013;24(8):2119-23
   PubMed Web of Science ®Google Scholar
• Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma 2013;54(9):1908-14
   PubMed Web of Science ®Google Scholar
• Liu Z, Dong HY, Gorczyca W, et al. CD5- mantle cell lymphoma. Am J Clin Pathol 2002;118(2):216-24
   PubMed Web of Science ®Google Scholar
• Barna G, Reiniger L, Tatrai P, et al. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematol Oncol 2008;26(3):167-70
   PubMedGoogle Scholar
• Kelemen K, Peterson LC, Helenowski I, et al. CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol 2008;130(2):166-77
   PubMed Web of Science ®Google Scholar
• Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84(8):2726-32
   PubMed Web of Science ®Google Scholar
• Siebert R, Matthiesen P, Harder S, et al. Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. Ann Oncol 1998;9(5):519-26
   PubMedGoogle Scholar
• Herens C, Lambert F, Quintanilla-Martinez L, et al. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. Blood 2008;111(3):1745-6
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008;111(12):5683-90
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94(11):1555-62
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106(13):4315-21
   PubMed Web of Science ®Google Scholar
• Hoster E. Prognostic relevance of clinical risk factors in mantle cell lymphoma. Semin Hematol 2011;48(3):185-8
   PubMedGoogle Scholar
• Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 2013;119(8):1570-7
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111(2):558-65
   PubMed Web of Science ®Google Scholar
• Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008;112(6):2583; author reply 2583-2584
   PubMedGoogle Scholar
• Mato AR, Svoboda J, Feldman T, et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 2012;118(14):3565-70;
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010;115(8):1530-3
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3(2):185-97
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006;107(8):3407
   PubMed Web of Science ®Google Scholar
• Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996;87(10):4302-10
   PubMed Web of Science ®Google Scholar
• Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the international prognostic index in patients with mantle cell lymphoma. Ann Oncol 2010;21(1):133-9
   PubMed Web of Science ®Google Scholar
• Shakir R, Ngo N, Naresh KN. Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma. J Clin Pathol 2008;61(8):920-7
   PubMedGoogle Scholar
• Dictor M, Ek S, Sundberg M, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica 2009;94(11):1563-8
   PubMed Web of Science ®Google Scholar
• Vegliante M, Palomero J, Pérez-Galán P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013;121:2175-85
   PubMed Web of Science ®Google Scholar
• Vegliante MC, Palomero J, Perez-Galan P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013;121(12):2175-85
   PubMed Web of Science ®Google Scholar
• Thorselius M, Walsh S, Eriksson I, et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol 2002;68(4):217-24
   PubMed Web of Science ®Google Scholar
• Bertoni F, Conconi A, Cogliatti SB, et al. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss group for clinical cancer research. Br J Haematol 2004;124(3):289-98
   PubMedGoogle Scholar
• Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011;118(11):3088-95
   PubMed Web of Science ®Google Scholar
• Cecconi D, Zamo A, Bianchi E, et al. Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 2008;8(21):4495-506
   PubMedGoogle Scholar
• Herrmann K, Buck AK, Schuster T, et al. A pilot study to evaluate 3′-deoxy-3′-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med 2011;52(12):1898-902
   PubMedGoogle Scholar
• Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 2010;37(9):1633-42
   PubMed Web of Science ®Google Scholar
• Cohen JB, Hall NC, Ruppert AS, et al. Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. Bone Marrow Transplant 2013;48(9):1212-17
   PubMed Web of Science ®Google Scholar
• Hosein PJ, Pastorini VH, Paes FM, et al. Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol 2011;86(10):841-5
   PubMed Web of Science ®Google Scholar
• Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20(5):1288-94
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367(6):520-31
   PubMed Web of Science ®Google Scholar
• Pott C. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance. Semin Hematol 2011;48(3):172-84
   PubMedGoogle Scholar
• Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP Plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and Autologous Stem Cell Transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP Plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2012;120:abstract 151
   Google Scholar
• Chen Z, Ayala P, Wang M, et al. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 2010;5(3):212-25
   PubMedGoogle Scholar
• Jung HJ, Chen Z, McCarty N. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. Leuk Lymphoma 2011;52(6):1066-79
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood 2005;105(7):2677-84
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16(4):587-93
   PubMed Web of Science ®Google Scholar
• Delarue R, Haioun C, Ribrag V, et al. RCHOP and RDHAP followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : final results of a Phase II study from the GELA. Blood 2008;112:abstract 581
   Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112(7):2687-93
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012;158(3):355-62
   PubMed Web of Science ®Google Scholar
• Kolstad A, Laurell A, Andersen N, et al. 90y-Ibritumumab Tiuxetan (Zevalin®)-BEAM/C with autologous stem cell support as frontline therapy for advanced mantle cell lymphoma. – preliminary results from the third nordic MCL Phase II study (MCL3). Blood 2009;114:932
   PubMedGoogle Scholar
• Laurell, Kolstad K, AnnaA, et al. Nordic MCL3 study: zevalin combined with high-dose chemotherapy followed by autologous stem cell support as late intensification for Mantle Cell Lymphoma (MCL) patients < 66 years not in CR after induction chemoimmunotherapy: no benefit of zevalin. Blood 2012;120:747
   Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and Autologous Stem Cell Transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2010;116:abstract 110
   Google Scholar
• Le Gouill S, Mary Callanan M, Elizabeth Macintyre E, et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study. Blood 2012;120:abstract 152
   Google Scholar
• Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010;150(2):200-8
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013;24(6):1587-93
   PubMed Web of Science ®Google Scholar
• Vose JM. Autotransplantation for mantle cell lymphoma. Cancer J 2012;18(5):427-31
   PubMedGoogle Scholar
• Till BG, Gooley TA, Crawford N, et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008;49(6):1062-73
   PubMed Web of Science ®Google Scholar
• Lacasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database. Blood 2012;119(9):2093-9
   PubMed Web of Science ®Google Scholar
• Feldman T, Mato A, Zielonka T, et al. Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). J Clin Oncol 2010;28(15a):abstract 8067
   Google Scholar
• Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Bone Marrow Transplant 2013. doi: 10.1038/bmt.2013.56
   PubMedGoogle Scholar
• Laurell A, Kolstad A, Jerkeman M, et al. High dose cytarabine with rituximab is not enough in first- line treatment of mantle cell lymphoma with high proliferation - early closure of the Nordic Lymphoma Group MCL5 Trial. Leuk Lymphoma 2013
   PubMedGoogle Scholar
• Rubio MT, Boumendil A, Luan JJ, et al. Is there still a place for Total Body Irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the lymphoma working party of the EBMT. Blood 2010;116:688
   Google Scholar
• Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007;48(7):1299-306
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clini Oncol 2005;23(15):3383-9
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(27):4473-9
   PubMed Web of Science ®Google Scholar
• Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol 2012;30:abstract 3
   Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117(10):2807-12
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013;31(11):1442-9
   PubMed Web of Science ®Google Scholar
• Chang JE, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 2011;155(2):190-7
   PubMedGoogle Scholar
• Kahl B, Li H, Smith M, et al. Mature results from ECOG study E1405. A phase II study of VcR-CVAD with maintenance rituximab for previously untreated mantle cell lymphoma. Blood 2012;120:abstract 153
   Google Scholar
• Houot R, Le Gouill S, Ojeda Uribe M, et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol 2011;23(6):1555-61
   PubMedGoogle Scholar
• Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008;113(1):108-16
   PubMedGoogle Scholar
• Spurgeon SE, Pindyck T, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2011;52(8):1488-94
   PubMed Web of Science ®Google Scholar
• Martin P, Leonard J. Is there a role for “watch and wait” in patients with mantle cell lymphoma? Semin Hematol 2011;48(3):189-93
   PubMedGoogle Scholar
• Eve HE, Furtado MV, Hamon MD, Rule SA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009;27(32):e189-90; author reply e191
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72(20):5307-16
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23(4):705-11
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2004;104(10):3064-71
   PubMed Web of Science ®Google Scholar
• Kenkre VP, Long WL, Eickhoff JC, et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 2011;52(9):1675-80
   PubMed Web of Science ®Google Scholar
• Arcaini L, Merli M. Rituximab maintenance in follicular lymphoma patients. World J Clin Oncol 2011;2(7):281-8
   PubMedGoogle Scholar
• Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003;14(10):1555-61
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Noy A, Pandit-Taskar N, et al. Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol 2006;24:7560
   Google Scholar
• Smith MR, Zhang L, Gordon L, et al. Phase II study of R-CHOP. followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: eastern cooperative oncology group study E1499. Blood 2007;110:389
   Google Scholar
• Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002;99(9):3158-62
   PubMed Web of Science ®Google Scholar
• Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26(1):90-5
   PubMed Web of Science ®Google Scholar
• Beaven AW, Shea TC, Moore DT, et al. A phase I study evaluating ibritumomab tiuxetan (Zevalin((R))) in combination with bortezomib (Velcade((R))) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012;53(2):254-8
   PubMed Web of Science ®Google Scholar
• Zent CS, Smith BJ, Ballas ZK, et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 2012;53(2):211-17
   PubMed Web of Science ®Google Scholar
• Bethge WA, Lange T, Meisner C, et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood 2010;116(10):1795-802
   PubMed Web of Science ®Google Scholar
• Issa F Khouri IF, Harrell R, Valverde R, et al. Stem cell transplantation with 90Yttrium Ibritumomab Tiuxetan(90YIT) in non-Hodgkin's Lymphoma (NHL): observations From PET pre-treatment imaging and responses in allografted refractory follicular histologies. Blood 2011;114:868
   Google Scholar
• Holman PR, Costello C, deMagalhaes-Silverman M, et al. Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012;18(2):257-64
   PubMed Web of Science ®Google Scholar
• Grant C, Neelapu SS, Kwak LW, et al. Eleven-Year follow-up of idiotype vaccine and DA-EPOCH-Rituximab in untreated mantle cell lymphoma: correlation of survival with idiotype immune response. Blood 2011;118:2707
   Google Scholar
• Goldstein MJ, Varghese B, Brody JD, et al. A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 2011;117(1):118-27
   PubMed Web of Science ®Google Scholar
• Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009;113(7):1581-8
   PubMed Web of Science ®Google Scholar
• Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14(10):3044-51
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012;23(1):166-71
   PubMed Web of Science ®Google Scholar
• Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson cancer center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113(18):4144-52
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000;6(6):640-5
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working Party of the European group for blood and bone marrow transplantation. Blood 2002;100(13):4310-16
   PubMed Web of Science ®Google Scholar
• Khouri IF, Champlin RE. Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 2004;31(1):22-6
   PubMedGoogle Scholar
• Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104(12):3535-42
   PubMed Web of Science ®Google Scholar
• Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14(11):1279-87. doi: 10.1016/j.bbmt.2008.08.014.
   PubMed Web of Science ®Google Scholar
• Fowler DH, Mossoba ME, Steinberg SM, et al. Phase II clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood 2013;121(15):2864-74
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans JC, Hoster E, Walewski J, et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma. Blood 2011;118:abstract 439
   Google Scholar
• Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99(9):706-14
   PubMed Web of Science ®Google Scholar
• Siegel AB, Goldenberg DM, Cesano A, et al. CD22-directed monoclonal antibody therapy for lymphoma. Semin Oncol 2003;30(4):457-64
   PubMed Web of Science ®Google Scholar
• Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28(12):2085-93
   PubMed Web of Science ®Google Scholar
• Younes A, Vose JM, Zelenetz AD, et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 2010;103(12):1783-7
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10(5):317-27
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Zugmaier G, Viardot A, et al. Confirmation of safety, efficacy and response duration in non-Hodgkin lymphoma patients treated with 60 µg/m2/d of BiTE® antibody blinatumomab. Blood 2009;114:abstract 2723
   Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24(30):4867-74
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20(3):520-5
   Google Scholar
• Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23(4):667-75
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23(4):676-84
   PubMed Web of Science ®Google Scholar
• Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18(1):116-21
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Moskowitz C, Portlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. Br J Haematol 2009;145(1):34-9
   PubMedGoogle Scholar
• Goy A, Bernstein SH, McDonald A, et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010;51(7):1269-77
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24(13):2105-12
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009;144(6):895-903
   PubMed Web of Science ®Google Scholar
• Gerecitano J, Portlock C, Moskowitz C, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 2009;146(6):652-5
   PubMedGoogle Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40
   PubMed Web of Science ®Google Scholar
• Barr PM, Fu P, Lazarus HM, et al. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol 2009;147(1):89-96
   PubMedGoogle Scholar
• Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma 2009;50(5):716-22
   PubMed Web of Science ®Google Scholar
• Alinari L, White VL, Earl CT, et al. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. mAbs 2009;1(1):31-40
   PubMed Web of Science ®Google Scholar
• Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011;96(7):1008-14
   PubMed Web of Science ®Google Scholar
• Gerecitano J, Portlock C, Hamlin P, et al. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res 2011;17(8):2493-501
   PubMedGoogle Scholar
• Perez-Galan P, Roue G, Villamor N, et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007;109(10):4441-9
   PubMed Web of Science ®Google Scholar
• Goy A, Ford P, Feldman T, et al. A phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma. Blood 2007;110:2569
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 2010;151(1):47-53
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Grant C, Hessler J, et al. Bortezomib + DA-EPOCH-R induction therapy followed by maintenance bortezomib versus observation in newly diagnosed mantle cell lymphoma. Blood 2012;120:abstract 3672
   Google Scholar
• Kumar S, Rajkumar SV. Many facets of bortezomib resistance/susceptibility. Blood 2008;112(6):2177-8
   PubMedGoogle Scholar
• Perez-Galan P, Mora-Jensen H, Weniger MA, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011;117(2):542-52
   PubMedGoogle Scholar
• O'Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15(22):7085-91
   PubMed Web of Science ®Google Scholar
• Stewart K, O'Connor O, Alsina M, et al. Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol 2007;25:abstract 8003
   Google Scholar
• Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012;18(17):4830-40
   PubMed Web of Science ®Google Scholar
• Andrew Spencer, Michael Millward, Paul Mainwaring, et al. Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052. Blood (ASH Annual Meeting Abstracts) 2009;114:2693
   Google Scholar
• Lee EC, Fitzgerald M, Bannerman B, et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011;17(23):7313-23
   PubMed Web of Science ®Google Scholar
• Kuhn J, Orlowski R, Bjorklund C. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 2011;11(3):285-95
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23(23):5347-56
   PubMed Web of Science ®Google Scholar
• Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113(3):508-14
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27(23):3822-9
   PubMed Web of Science ®Google Scholar
• Renner C, Zinzani P, Gressin R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012;97(7):1085-91
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25(2):341-7
   PubMed Web of Science ®Google Scholar
• Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011;12(4):361-8
   PubMed Web of Science ®Google Scholar
• Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21(9):1740-5
   PubMed Web of Science ®Google Scholar
• Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010;28(3):418-23
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26(30):4952-7
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22(7):1622-7
   PubMed Web of Science ®Google Scholar
• Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116(17):3227-37
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica 2009;94(9):1198-202
   PubMed Web of Science ®Google Scholar
• Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013;161(5):695-700
   PubMed Web of Science ®Google Scholar
• Broyl A, Kuiper R, van Duin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013;121(4):624-7
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118(18):4771-9
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104(8):2269-71
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2009;27(32):5404-9
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145(3):344-9
   PubMed Web of Science ®Google Scholar
• Zinzani P, Witzig T, ose J, et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003). Blood 2008;212:262
   Google Scholar
• Eve HE, Rule SA. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. Br J Haematol 2010;151(4):410-12
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams M, et al. Phase II multicenter study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: the MCL-001 “EMERGE” study. Blood 2012;120:abstract 905
   Google Scholar
• Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84(9):553-9
   PubMed Web of Science ®Google Scholar
• Qian Z, Zhang L, Cai Z, et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 2011;35(3):380-6
   PubMedGoogle Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13(7):716-23
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118(13):3603-12
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117(2):591-4
   PubMed Web of Science ®Google Scholar
• Kahl B, Byrd J, Flinn I, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116:1777
   Web of Science ®Google Scholar
• Iyengar S, Clear A, Bodor C, et al. P110alpha mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013;21(12):2274-84
   Google Scholar
• de Vos S, Schreeder M, Flinn I, et al. A Phase 1 study of the selective Phosphatidylinositol 3-Kinase-Delta (PI3K) inhibitor, Cal-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with previously treated, Indolent Non-Hodgkin Lymphoma (iNHL). Blood 2011;118:2699
   Google Scholar
• Horwitz S, Flinn I, Patel M, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma. J Clin Oncol 2013;31:abstract 8518
   Google Scholar
• Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118(16):4313-20
   PubMed Web of Science ®Google Scholar
• Irish JM, Myklebust JH, Alizadeh AA, et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 2010;107(29):12747-54
   PubMed Web of Science ®Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics 1952;9(6):722-8
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119(5):1182-9
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2012;31(1):88-94
   PubMed Web of Science ®Google Scholar
• O'Brien S, Burger J, Blum K, et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): follow-up of a Phase Ib/II Study. Blood 2011;118:983
   Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16
   PubMed Web of Science ®Google Scholar
• Davids M, Roberts A, Anderson M, et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood 2012;120:abstract 304
   Google Scholar